Lonsurf (trifluridine/tipiracil) / Otsuka 
Welcome,         Profile    Billing    Logout  
 6 Diseases   125 Trials   125 Trials   2571 News 


«12...910111213141516171819...3334»
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Review, Journal:  A Case of Neuroendocrine Carcinoma of the Stomach Treated with TAS-102 (Pubmed Central) -  Oct 26, 2022   
    For treatment of recurrence, SP therapy(S-1 and cisplatin), ramucirumab plus weekly paclitaxel therapy, and nivolumab were administered in that order...The appropriate timing for switching drug therapy may be important in the future. We report a favorable therapeutic effect of TAS-102 after immune checkpoint inhibitor treatment along with a review of the literature.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal:  A Case of Pembrolizumab Therapy Markedly Effective for Advanced Recurrent Colorectal Cancer (Pubmed Central) -  Oct 26, 2022   
    FOLFIRI plus ramucirumab therapy and FTD/TPI were introduced as the second-line and third-line treatments, respectively; however, recurrent lymph nodes were further exacerbated and showed treatment resistance...After the therapy, the lymph nodes reduced markedly. The patient remains undergoing chemotherapy without any adverse events.
  • ||||||||||  Tibsovo (ivosidenib) / Servier
    Journal, PD(L)-1 Biomarker, IO biomarker:  An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma. (Pubmed Central) -  Oct 20, 2022   
    Systemic therapy options such as the combination of 5-flurouracil (5-FU) and oxaliplatin (FOLFOX), 5-FU and liposomal irinotecan, and trifluridine/tipiracil (TAS-102) and irinotecan have shown encouraging results...Ivosidenib is an excellent option for IDH1-mutant cholangiocarcinoma that progressed on first-line chemotherapy given its excellent tolerability and median OS benefit. However, a few questions remain unanswered - sequencing of targeted therapies, benefits of combining targeted therapy with systemic chemotherapy or with other treatment modalities, such as immunotherapy and localized therapies.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Trial completion date, Metastases:  TAS-102 in Treating Advanced Biliary Tract Cancers (clinicaltrials.gov) -  Oct 14, 2022   
    P2,  N=28, Active, not recruiting, 
    Our series provides further evidence on the activity and safety of the combination of trifluridine-tipiracil and bevacizumab in a real-world series of Western refractory mCRC patients. Trial completion date: Sep 2022 --> Dec 2022
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche, Stivarga (regorafenib) / Bayer
    Journal:  Value-Based Analysis of Therapies in Refractory Metastatic Colorectal Cancer in US. (Pubmed Central) -  Oct 12, 2022   
    Recruiting --> Active, not recruiting The optimum dosing strategy for regorafenib has improved its benefit-to-toxicity ratio and relative cost-effectiveness compared to RSD, TAS-102, and TAS-BEV.
  • ||||||||||  Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Third- and Late Line Treatments of Metastatic Gastric Cancer: Still More to Be Done. (Pubmed Central) -  Sep 24, 2022   
    Overall, TAS-102, apatinib, regorafenib, nilotinib, trastuzumab, and pembrolizumab were demonstrated to be valid options in the third line scenario for mGC patient refractory to at least two lines of therapy. A multimodal approach based on chemotherapy, immunotherapy, targeted agents, a personalised nutritional programme as well as the research of new predictive biomarkers may pave the way to new strategies to identify the best treatment for each patient.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Trial completion date, Trial termination, Combination therapy, Metastases:  Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs (clinicaltrials.gov) -  Sep 23, 2022   
    P1,  N=18, Terminated, 
    A multimodal approach based on chemotherapy, immunotherapy, targeted agents, a personalised nutritional programme as well as the research of new predictive biomarkers may pave the way to new strategies to identify the best treatment for each patient. Trial completion date: Aug 2024 --> Jan 2022 | Active, not recruiting --> Terminated; closed per sponsor request, for slow enrollment
  • ||||||||||  ASP1570 / Astellas
    Phase classification, Trial completion date, Trial primary completion date, Monotherapy:  KEYNOTE-E59: A Study of ASP1570 Alone or in Combination With Pembrolizumab or Standard Therapies in Adults With Solid Tumors (clinicaltrials.gov) -  Sep 8, 2022   
    P1/2,  N=168, Recruiting, 
    However, this combination did not achieve meaningful clinical benefit in patients with RAS-mutated PIK3CA and PTEN wild-type refractory mCRC. Phase classification: P1 --> P1/2 | Trial completion date: Aug 2026 --> Apr 2027 | Trial primary completion date: Aug 2026 --> Apr 2027
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Cyramza (ramucirumab) / Eli Lilly, Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker:  European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions. (Pubmed Central) -  Sep 3, 2022   
    Beyond this, efficacy has been demonstrated with oral trifluridine/tipiracil and with single-agent nivolumab, in selected refractory patients. In this review, we highlight the positive evidence from key trials that have led to our current practice algorithm, with particular focus on the refractory advanced disease setting, discussing the areas of active research and highlighting the factors, including biomarkers and the influence of ethnicity, that contribute to therapeutic decision-making.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Halaven (eribulin mesylate) / Eisai
    Did You Just Get a NICE Increase in Price Potential? Severity Multipliers and Price Potential in England (Virtual) -  Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_493;    
    While the introduction of severity modifiers is intended to be healthcare budget neutral, there will be winners and losers. Going forward, quality-adjusted life expectancy of the general population, and shortfalls in both life expectancy and quality of life under current standard of care for a health condition will determine the applicable WTP threshold.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Erbitux (cetuximab) / Eli Lilly
    Trial initiation date, Combination therapy, Metastases:  Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC (clinicaltrials.gov) -  Aug 30, 2022   
    P1,  N=6, Recruiting, 
    Going forward, quality-adjusted life expectancy of the general population, and shortfalls in both life expectancy and quality of life under current standard of care for a health condition will determine the applicable WTP threshold. Initiation date: Dec 2021 --> Aug 2022
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Fruzaqla (fruquintinib) / Takeda
    Enrollment open, Metastases:  Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC (clinicaltrials.gov) -  Aug 18, 2022   
    P2,  N=54, Recruiting, 
    Finally, our data suggest a tendency toward the use of trifluridine-tipiracil (SWI: 79%; INT: 66%) over regorafenib (SWI: 18%; INT: 18%) as the preferred third-line treatment choice in mCRC patients regardless of KRAS status. Not yet recruiting --> Recruiting
  • ||||||||||  Yutuo (zimberelimab) / Arcus Biosci, Gilead
    Enrollment change, Metastases:  AB122 Platform Study (clinicaltrials.gov) -  Aug 9, 2022   
    P1,  N=292, Recruiting, 
    Initiation date: Jul 2022 --> Nov 2022 N=180 --> 292
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
    Enrollment closed, Combination therapy:  Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer (clinicaltrials.gov) -  Aug 2, 2022   
    P2,  N=27, Active, not recruiting, 
    Trial completion date: Mar 2027 --> Dec 2027 | Initiation date: May 2022 --> Dec 2022 Not yet recruiting --> Active, not recruiting
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
    PROMETCO study: Metastatic colorectal cancer treatment patterns of the first 531 enrolled patients (Poster Area, Hall 4) -  Jul 28, 2022 - Abstract #ESMO2022ESMO_2389;    
    P=N/A
    At inclusion, pts had prior exposure to fluoropyrimidine (98%), oxaliplatin (84%), irinotecan (88%) and anti-VEGF (75%), and 68%/23% of the pts had a previous colorectal/liver surgery, respectively...In 3L and 4L, 68% and 38% received FTD/TPI and 14% and 43% received regorafenib, respectively...In 1L and 2L, most of the pts received CT doublet/triplet + anti-VEGF/EGFR. In-depth analysis is planned to better understand the 3L and 4L treatment allocation (based on access to treatment options locally).